Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlinkā„¢ technology, the first ADCs are addressing molecular targets for which they have already shown clinical promise.

Mablink is currently developing three ADC programs based on a camptothecin derivative (a topoisomerase I inhibitor) as payload:

Discovery

Preclinical

Phase I

Phase II

Disc.

Precl.

Ph. I

Ph. II

MBK-101

Acute Myeloid leukemia

Preclinical

MBK-102

Multiple Myeloma

Preclinical

MBK-103

Solid Tumors

Preclinical